Brief: Adial Pharmaceuticals Provides Update On Regulatory Strategy For AD04
March 6 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS PROVIDES UPDATE ON REGULATORY
STRATEGY FOR
AD04 FOR TREATMENT OF ALCOHOL USE DISORDER
* ADIAL PHARMACEUTICALS INC - TO PURSUE PATH TOWARD U.S. AND
EUROPEAN APPROVALS; TYPE C MEETING WITH FDA CONFIRMED FOR Q2
2023
* ADIAL PHARMACEUTICALS INC - TYPE C MEETING WITH FDA
CONFIRMED
FOR Q2 2023 TO DISCUSS CLINICAL PROGRAM IN U.S.
* ADIAL PHARMACEUTICALS INC - PLANS IN PLACE TO MEET WITH
MULTIPLE
EUROPEAN REGULATORY AUTHORITIES
Source text for Eikon: ID:nGNX1tGQGK
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)